Axovant Sciences (NASDAQ:AXON) Given Hold Rating at Cowen

Cowen reissued their hold rating on shares of Axovant Sciences (NASDAQ:AXON) in a research report sent to investors on Thursday, September 20th.

AXON has been the subject of a number of other reports. Jefferies Financial Group increased their target price on shares of Axovant Sciences from $3.00 to $5.00 and gave the company a hold rating in a report on Monday, June 11th. BidaskClub cut shares of Axovant Sciences from a sell rating to a strong sell rating in a report on Wednesday, September 12th. Zacks Investment Research cut shares of Axovant Sciences from a strong-buy rating to a hold rating in a report on Friday, June 15th. ValuEngine lowered shares of Axovant Sciences from a hold rating to a sell rating in a research report on Monday, June 11th. Finally, Chardan Capital reiterated a hold rating and issued a $4.00 price target on shares of Axovant Sciences in a research report on Wednesday, June 6th. Two research analysts have rated the stock with a sell rating, six have given a hold rating and two have given a buy rating to the stock. The stock currently has an average rating of Hold and a consensus target price of $4.85.

Axovant Sciences stock traded up $0.19 during mid-day trading on Thursday, reaching $2.34. The company had a trading volume of 1,350,191 shares, compared to its average volume of 2,744,320. Axovant Sciences has a 1 year low of $1.02 and a 1 year high of $6.59. The company has a current ratio of 2.34, a quick ratio of 2.34 and a debt-to-equity ratio of 1.48. The stock has a market cap of $295.44 million, a PE ratio of -1.14 and a beta of -0.01.

Axovant Sciences (NASDAQ:AXON) last issued its earnings results on Tuesday, August 7th. The biotechnology company reported ($0.48) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.15) by ($0.33). On average, sell-side analysts forecast that Axovant Sciences will post -1.67 EPS for the current fiscal year.

In other Axovant Sciences news, Director George Bickerstaff purchased 25,000 shares of the stock in a transaction dated Thursday, August 9th. The shares were acquired at an average cost of $2.07 per share, for a total transaction of $51,750.00. Following the completion of the transaction, the director now directly owns 50,000 shares of the company’s stock, valued at $103,500. The purchase was disclosed in a filing with the SEC, which is available at this link. 6.00% of the stock is owned by corporate insiders.

Several hedge funds have recently added to or reduced their stakes in AXON. Tower Research Capital LLC TRC grew its position in shares of Axovant Sciences by 1,627.0% in the second quarter. Tower Research Capital LLC TRC now owns 62,139 shares of the biotechnology company’s stock valued at $141,000 after purchasing an additional 58,541 shares during the last quarter. JPMorgan Chase & Co. boosted its position in Axovant Sciences by 2,519.0% during the first quarter. JPMorgan Chase & Co. now owns 183,223 shares of the biotechnology company’s stock worth $244,000 after acquiring an additional 176,227 shares during the last quarter. GSA Capital Partners LLP acquired a new stake in Axovant Sciences during the second quarter worth approximately $338,000. Paloma Partners Management Co acquired a new stake in Axovant Sciences during the second quarter worth approximately $356,000. Finally, A.R.T. Advisors LLC boosted its position in Axovant Sciences by 148.9% during the first quarter. A.R.T. Advisors LLC now owns 416,302 shares of the biotechnology company’s stock worth $553,000 after acquiring an additional 249,074 shares during the last quarter. Institutional investors and hedge funds own 9.38% of the company’s stock.

Axovant Sciences Company Profile

Axovant Sciences Ltd., a clinical-stage biopharmaceutical company, engages in acquisition, development, and commercialization of therapeutics in the fields of neurology and psychiatry in the United States and the European Union. It focuses on developing AXO-Lenti-PD, an in vivo lentiviral gene therapy investigational product candidate for the one-time treatment of Parkinson's disease.

Read More: What is a closed-end mutual fund (CEF)?

Analyst Recommendations for Axovant Sciences (NASDAQ:AXON)

Receive News & Ratings for Axovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply